ArticleMolecular medicine (Cambridge, Mass.)2026
A TRIM15-CDX2 loop drives bile acid-induced gastric intestinal metaplasia.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGastric intestinal metaplasia (GIM), a precancerous lesion and risk factor for gastric cancer, is closely associated with chronic bile acid (BA) exposure; however, its molecular mechanisms remain unclear. This study aimed to identify key regulators involved in BA-associated GIM and to elucidate their functional roles.
methodsTRIM15 and GIM markers (CDX2, MUC2, KLF4, and VIL1) were assessed in human GIM and paired normal tissues by RNA-seq, RT‒qPCR, Western blotting (WB), and immunofluorescence (IF). BA profiles were analyzed using UHPLC‒MS/MS. In vitro, GES-1 cells were treated with CDCA and subjected to TRIM15 gain- and loss-of-function assays. CDX2-mediated transcriptional regulation of TRIM15 was evaluated by dual-luciferase reporter and ChIP assays. NF-κB signaling and related proteins were assessed by WB and IF. The interaction between TRIM15 and IκBα and the levels of ubiquitination were investigated by coimmunoprecipitation, LC-MS/MS and protein-protein docking analysis. Functional assays were used to assess proliferation and apoptosis. In vivo validation was performed using an AAV9-mediated TRIM15 knockdown rat model.
resultsTRIM15 expression was consistently upregulated in GIM and increased stepwise with disease severity, accompanied by a positive association with CDX2 expression. BA profiling revealed the selective enrichment of cholic acid (CA) and chenodeoxycholic acid (CDCA), which induced GIM-associated phenotypes in vitro. Mechanistically, CDX2 directly bound to the TRIM15 promoter to increase its transcription, whereas TRIM15 promoted CDX2 expression via the NF-κB pathway, resulting in the formation of a regulatory loop. Further mechanistic analyses revealed that TRIM15 promoted K48-linked ubiquitination and subsequent proteasomal degradation of IκBα, thereby enhancing p65 phosphorylation. Notably, this effect was abolished by expression of the degradation-resistant IκBα S32A/S36A mutant. In vivo, TRIM15 knockdown attenuated gastric mucosal injury and intestinal metaplasia and reduced NF-κB signaling and CDX2 expression.
conclusionThese findings suggest the involvement of a TRIM15-NF-κB-CDX2 regulatory loop in BA-associated GIM. TRIM15 may contribute to epithelial reprogramming under BA exposure and could be a potential biomarker and therapeutic target for GIM progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.